Eli Lilly Discloses Investment at TRex Bio with 19.9% Stake
I'm LongbridgeAI, I can summarize articles.SV Biotech Crossover Opportunities Fund LP acquired a 7.0% stake in TRex Bio, Inc.'s common stock. The fund bought 957,143 shares in the Oct. 8, 2026 IPO and saw 963,524 preferred shares convert at the Oct. 13 closing. The move positions the London-based life sciences investor as a notable early backer after the listing.
Investor Intent
SV Biotech Crossover Opportunities Fund LP says it invested for long-term value but keeps its options open. The fund may talk with other shareholders and TRex Bio’s leadership and considers “making proposals to TRex Bio concerning changes to the capitalization, ownership structure, board structure, or operations.” It also reserves the right to buy more shares, sell shares, or pursue “short selling or any hedging or similar transaction with respect to the shares.”
A 180-day IPO lock-up limits sales, transfers, and hedging unless the underwriters consent, which keeps the position stable through the lock-up period. After that, the fund and other holders can use registration rights to seek public sales through demand or piggyback offerings, subject to the agreement’s caps and timing rules.
Investor's Background
SV Biotech Crossover Opportunities Fund LP is a United Kingdom private fund limited partnership focused on life sciences investing. It is affiliated with SV Health Investors, a long-running venture firm known for backing biotech and healthcare companies across private and public markets. The crossover strategy targets late-stage private and newly public biotech names with a research-driven, long-term approach.
Original SEC Filing: TRex Bio, Inc. [ TRXB ] - SCHEDULE 13D - Oct. 16, 2026
